Genetic testing for FLT3 internal tandem duplication (FLT3-ITD), NPM1, andCEBPA variants may be considered medically necessary in cytogenetically normal acute myeloid leukemia (see Policy Guidelines section).
Genetic testing for FLT3-ITD , NPM1, and CEBPA variants is considered investigational in all other situations.
Genetic testing for FLT3 tyrosine kinase domain variants is considered investigational.
Genetic testing for FLT3, NPM1, and CEBPA variants to detect minimal residual disease is considered investigational.
